These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20845250)

  • 1. [Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema].
    Kakkassery V; Winterhalter S; Joussen AM
    Klin Monbl Augenheilkd; 2010 Sep; 227(9):701-11. PubMed ID: 20845250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology.
    Ho AC; Scott IU; Kim SJ; Brown GC; Brown MM; Ip MS; Recchia FM
    Ophthalmology; 2012 Oct; 119(10):2179-88. PubMed ID: 22917890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues.
    Stewart MW
    Curr Diabetes Rev; 2012 Jul; 8(4):237-46. PubMed ID: 22515701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic macular edema.
    Lang GE
    Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [From scientific evidence to clinical practice: treatment protocols for diabetic macular edema].
    López-Gálvez MI; García-Campos JM
    Arch Soc Esp Oftalmol; 2012 Dec; 87 Suppl 1():38-45. PubMed ID: 24278988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for anti-VEGF treatment of diabetic macular edema.
    Bandello F; Berchicci L; La Spina C; Battaglia Parodi M; Iacono P
    Ophthalmic Res; 2012; 48 Suppl 1():16-20. PubMed ID: 22907145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-VEGF therapeutic approaches for diabetic macular edema.
    Khurana RN; Do DV; Nguyen QD
    Int Ophthalmol Clin; 2009; 49(2):109-19. PubMed ID: 19349791
    [No Abstract]   [Full Text] [Related]  

  • 10. Current intravitreal pharmacologic therapies for diabetic macular edema.
    Colucciello M
    Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
    O'Malley PG
    Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
    [No Abstract]   [Full Text] [Related]  

  • 12. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
    Ajlan RS; Silva PS; Sun JK
    Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.
    Avery RL; Gordon GM
    JAMA Ophthalmol; 2016 Jan; 134(1):21-9. PubMed ID: 26513684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diabetic maculopathy. Diagnosis and treatment].
    Gelisken F; Ziemssen F
    Ophthalmologe; 2010 Aug; 107(8):773-86; quiz 787-8. PubMed ID: 20658139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor agents for diabetic maculopathy.
    Salam A; DaCosta J; Sivaprasad S
    Br J Ophthalmol; 2010 Jul; 94(7):821-6. PubMed ID: 19556214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary.
    Giuliari GP; Guel DA; Cortez MA; Cortez RT
    Can J Ophthalmol; 2010 Oct; 45(5):501-8. PubMed ID: 20648074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-VEGF Molecules for the Management of Diabetic Macular Edema.
    Bandello F; Cicinelli MV; Parodi MB
    Curr Pharm Des; 2015; 21(32):4731-7. PubMed ID: 26350530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal anti-VEGF drugs as adjuvant therapy in diabetic retinopathy surgery.
    Montero JA; Ruiz-Moreno JM; Correa ME
    Curr Diabetes Rev; 2011 May; 7(3):176-84. PubMed ID: 21438852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.